Smith Scott E 4

Accession 0001179110-11-015981

CIK 0001222244other

Filed

Dec 1, 7:00 PM ET

Accepted

Dec 2, 5:00 PM ET

Size

21.6 KB

Accession

0001179110-11-015981

Form 4

Period: 2011-12-01

Director

Transactions

Award
Common stock, $0.0001 par value
2011-12-01$1.10/sh+11,819$13,001→ 160,702 total
Award
Convertible Note
2011-12-01$1.00/sh
Exercise: $1.10Exp: 2012-02-28→ Common stock, $0.00001 par value

Holdings

Stock Options
Exercise: $1.00Exp: 2015-08-12→ Common stock, $0.00001 par value (1,000 underlying)
1,000
Stock Options
Exercise: $1.25Exp: 2016-08-11→ Common Stock, $0.00001 par value (1,000 underlying)
1,000
Warrants
Exercise: $1.30Exp: 2014-01-07→ Common stock, $0.00001 par value (10,000 underlying)
10,000
Stock Options
Exercise: $7.00Exp: 2013-05-30→ Common Stock, $0.00001 par value (3,000 underlying)
3,000
Warrants
Exercise: $0.70Exp: 2012-12-31→ Common Stock, $0.00001 par value (7,000 underlying)
7,000
Stock Options
Exercise: $0.85Exp: 2016-03-03→ Common stock, $0.00001 par value (20,000 underlying)
20,000
Stock options
Exercise: $1.50Exp: 2016-09-29→ Common stock, $0.00001 par value (30,000 underlying)
30,000
Warrants
Exercise: $1.30Exp: 2012-11-12→ Common stock, $0.00001 par value (20,000 underlying)
20,000
Warrants
Exercise: $1.30Exp: 2013-07-12→ Common stock, $0.00001 par value (32,475 underlying)
32,475
Stock options
Exercise: $0.87Exp: 2018-08-09→ Common stock, $0.00001 par value (28,736 underlying)
28,736
Options
Exercise: $1.72Exp: 2017-08-10→ Common stock $0.00001 par value (14,535 underlying)
14,535

Footnotes (5)

[F1]Currently exercisable.
[F2]Options shall vest on the latter of the date that the Company is cleared by the FDA to sell the ProUroScan System in the United States or the date the Company closes on an aggregate of $2,000,000 or more of incremental equity financing after the date of grant(including the exercise of existing warrants).
[F3]Annual option award pursuant to the Issuer's compensation policy for Directors upon their re-election to the Board of Directors at its annual shareholders' meeting. The seven-year options vest ratably over 12 months.
[F4]Shares issued in lieu of cash for directors' fees as approved by the Board of Directors which are exempt under section 16b-3(d).
[F5]On December 1, 2011, the reporting person and the Company executed a convertible promissory note in the principal amount of $6,400 with a maturity date of February 28, 2012. The principal amount and interest accruing at a rate of 10% per year are convertible into common shares at $1.10 per share at any time through the maturity date. The number of shares to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within 2 business days after conversion. The transaction was approved by the Company's Board of Directors and is exempt under section 16b-3(d).

Documents

1 file

ProUroCare Medical Inc.

CIK 0001222244

Entity typeother